Glaxo set to profit from US ruling
Saturday 21 June 1997
The decision grants Toronto-based Genpharm exclusive rights to the huge US ranitidine (generic Zantac) market between 25 July - the day Glaxo's branded Zantac loses its US patent - and August 29th. This will keep hordes of other generic companies out of the market, allowing Glaxo and Genpharm a short, but highly profitable monopoly.
Glaxo, which currently makes pounds 3m a day from US Zantac sales, faced losing 80 per cent of that market when other companies flooded in on July 25th. With only one generic in the market, the Zantac brand price would not fall as far and fast as had been feared. Analysts say Genpharm will want to keep market prices high, as it is being sued by Glaxo for infringing the Zantac patent. Anthony Colletta, analyst at Hoare Govett said: "Genpharm will want to make profits fast. If it loses the case, it will have to pay triple in compensation back to Glaxo."
Though Glaxo said it is "not in a position to evaluate" the effect of the ruling on Zantac sales, it stands to benefit in other ways too. As part of a settlement of disputes over the validity of ranitidine, Glaxo recently signed an agreement, for which it got a reputed pounds 75m, giving another generic group Novopharm the right to sell ranitidine from 10th July, 15 days ahead of the Zantac patent expiry. If the ruling granting Genpharm exclusive rights is upheld and Novopharm is not the first in, Glaxo will have an extra 15 days to sell Zantac unopposed. Novopharm is appealing vigorously against the ruling.
One loser in all this could be Holliday Chemicals, the world's biggest supplier of ranitidine. Though Holliday does supply other groups including Genpharm, its biggest and exclusive licence is with Novopharm. If Novopharm loses the all-important right to be first into the market - which means it can tie up customers at good prices - Hollidays sales would suffer. Holliday's share price has risen steeply on prospects of a huge rise in ranitidine sales. Michael Eastwood from Kleinwort Benson, says that pounds 4m of his pounds 23m 1997 profit forecast for Holliday is on the potential of the US ranitidine market alone. A more serious issue is if Holliday loses a patent infringement case brought by Glaxo against its Spanish subsidiary Uquifa which manufactures rantidine. Should it lose, supplies of ranitidine would dry up and Holliday would suffer. Glaxo, by contrast, would have two years of relatively unopposed Zantac sales.
- 1 This restaurant has misunderstood the concept of 'cheese and biscuits'
- 2 Raif Badawi, the Saudi Arabian blogger sentenced to 1,000 lashes, may now face death penalty
- 3 Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
- 4 PornHub turns masturbation into energy in bid to save the planet
- 5 Have sex with your iPad thanks to the new sex toy no-one asked for
Raif Badawi, the Saudi Arabian blogger sentenced to 1,000 lashes, may now face death penalty
Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
PornHub turns masturbation into energy in bid to save the planet
Spiritual leader allegedly manipulated 400 men into removing testicles to be 'closer to God'
The 'sex selfie stick' lets you FaceTime the inside of a vagina
New theory could prove how life began and disprove God
This is what it's like to be dead, according to a guy who died for a bit
End of the licence fee: BBC to back radical overhaul of how it is funded
'Jihadi John': CAGE representative storms off Sky News accusing Kay Burley of Islamophobia
Ukip would cut billions from Scottish budget to fund English tax cuts
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
iJobs Money & Business
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
£15000 - £16000 per annum: Recruitment Genius: A Customer Service Advisor is r...
£22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...
£40000 - £50000 per annum + pro rata: SThree: SThree Group have been well esta...